LOS ANGELES — Lifitegrast demonstrated positive results for the treatment of dry eye disease at a rapid rate, according to a study presented at the American Society of Cataract and Refractive Surgery meeting.
The study investigated the impact of Xiidra (lifitegrast ophthalmic solution 5%, Bausch + Lomb) on dry eye biomarkers and patient satisfaction, Eric D. Donnenfeld, MD, told Healio.
“As early as 2 weeks, patients showed a significant improvement in comfort based on subjective comfort scores,” he said.
The anti-inflammatory T-cell modulator also yielded significant